Old Web
English
Sign In
Acemap
>
Paper
>
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF
2021
Vanessa Welk
Marina Pavlidou
Claudia Wurzenberger
Eva-Maria Hansbauer
Cornelia Wurzenberger
Stefan Gruner
Janet Peper-Gabriel
Thomas Jaquin
Antonio Konitsiotis
Josefine Morgenstern
Josef Prassler
Gabriele Matschiner
Shane Olwill
Keywords:
Oncology
Class (biology)
CTGF
Internal medicine
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]